List of Karbinal Er drug patents

Karbinal Er is owned by Aytu.

Karbinal Er contains Carbinoxamine Maleate.

Karbinal Er has a total of 2 drug patents out of which 0 drug patents have expired.

Karbinal Er was authorised for market use on 28 March, 2013.

Karbinal Er is available in suspension, extended release;oral dosage forms.

The generics of Karbinal Er are possible to be released after 29 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522191 AYTU Modified release formulations containing drug—ion exchange resin complexes
Jun, 2027

(4 years from now)

US8062667 AYTU Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(6 years from now)

Drugs and Companies using CARBINOXAMINE MALEATE ingredient

Market Authorisation Date: 28 March, 2013

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in